{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T21:50:35Z","timestamp":1794433835801,"version":"4.9.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T00:00:00Z","timestamp":1705536000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T00:00:00Z","timestamp":1705536000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>We describe 1000 patients with essential thrombocythemia seen at the Center Research and Innovation of Myeloproliferative Neoplasms (CRIMM), Florence, Italy, between 1980 and 2023: median age 59 years (18\u201395), females 65%, <jats:italic>JAK2<\/jats:italic>\/<jats:italic>CALR<\/jats:italic>\/<jats:italic>MPL<\/jats:italic>-mutated 66%\/19%\/4%, triple-negative (TN) 11%. Extreme thrombocytosis (ExT, platelets \u22651000\u2009\u00d7\u200910<jats:sup>9<\/jats:sup>\/L) in 16%, leukocytosis (leukocytes &gt;11\u2009\u00d7\u200910<jats:sup>9<\/jats:sup>\/L) in 16%, and at least one cardiovascular risk factor in 52% of cases. <jats:italic>JAK2<\/jats:italic>-mutated patients were older (median 62 years) and <jats:italic>CALR<\/jats:italic>-mutated and TN (53 years for both) younger (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). Female gender clustered with TN (76%) and <jats:italic>JAK2<\/jats:italic> (67%) vs <jats:italic>CALR<\/jats:italic> (46%) mutations (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). ExT clustered with <jats:italic>CALR<\/jats:italic> (type-2 more than type-1), TN and <jats:italic>MPL<\/jats:italic>, and leukocytosis with <jats:italic>JAK2<\/jats:italic> mutation (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). In multivariable analysis, risk factors for arterial thrombosis-free survival were age \u226560 years (HR 2.0; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) and <jats:italic>JAK2<\/jats:italic> mutation (HR 1.3; <jats:italic>p<\/jats:italic>\u2009=\u20090.02) with borderline significance for male gender (<jats:italic>p<\/jats:italic>\u2009=\u20090.08) and cardiovascular risk factors (<jats:italic>p<\/jats:italic>\u2009=\u20090.08); for venous thrombosis-free survival, <jats:italic>JAK2<\/jats:italic> mutation (HR 1.9; <jats:italic>p<\/jats:italic>\u2009=\u20090.03) with borderline significance for venous thrombosis history (<jats:italic>p<\/jats:italic>\u2009=\u20090.07); for overall survival, older age (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), male gender (HR 1.9; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), absolute neutrophil count (ANC)\u2009\u2265\u20098\u2009\u00d7\u200910<jats:sup>9<\/jats:sup>\/L (HR 1.8; <jats:italic>p<\/jats:italic>\u2009=\u20090.01), absolute lymphocyte count (ALC)\u2009&lt;\u20091.7\u2009\u00d7\u200910<jats:sup>9<\/jats:sup>\/L (HR 1.2; <jats:italic>p<\/jats:italic>\u2009=\u20090.03); for myelofibrosis-free survival, <jats:italic>CALR<\/jats:italic> mutation (HR 2.7; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001, particularly for <jats:italic>CALR<\/jats:italic> type 1\/1-like, HR 3.3) and <jats:italic>MPL<\/jats:italic> mutation (HR 3.9; <jats:italic>p<\/jats:italic>\u2009=\u20090.001); for leukemia-free survival, older age (<jats:italic>p<\/jats:italic>\u2009=\u20090.03). Cytoreductive therapy appeared to mitigate both venous (HR 0.3; <jats:italic>p<\/jats:italic>\u2009=\u20090.01) and arterial thrombosis (HR 4; <jats:italic>p<\/jats:italic>\u2009=\u20090.04); there was a trend for aspirin in preventing arterial thrombosis recurrence. The current study provides real-world observations in essential thrombocythemia, representing a valid source document for interpreting current literature and planning future studies.<\/jats:p>","DOI":"10.1038\/s41408-023-00968-7","type":"journal-article","created":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T08:02:34Z","timestamp":1705564954000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["One thousand patients with essential thrombocythemia: the Florence-CRIMM experience"],"prefix":"10.1038","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6241-1206","authenticated-orcid":false,"given":"Giuseppe G.","family":"Loscocco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Gesullo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulio","family":"Capecchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Atanasio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Maccari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4810-6501","authenticated-orcid":false,"given":"Francesco","family":"Mannelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5755-0730","authenticated-orcid":false,"given":"Alessandro M.","family":"Vannucchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1809-284X","authenticated-orcid":false,"given":"Paola","family":"Guglielmelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,18]]},"reference":[{"key":"968_CR1","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/BF01891529","volume":"293","author":"EGA Epstein","year":"1934","unstructured":"Epstein EGA. Haemorrhagische thrombocythamie bei vascularer schrumpfmilz. Virchows Arch A Pathol Anat Histopathol. 1934;293:233\u201347.","journal-title":"Virchows Arch A Pathol Anat Histopathol"},{"key":"968_CR2","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","volume":"140","author":"DA Arber","year":"2022","unstructured":"Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka H-M, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140:1200\u201328.","journal-title":"Blood"},{"key":"968_CR3","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: myeloid and histiocytic\/dendritic neoplasms. Leukemia. 2022;36:1703\u201319.","journal-title":"Leukemia"},{"key":"968_CR4","doi-asserted-by":"crossref","unstructured":"Coltro G, Loscocco GG, Vannucchi AM. Classical Philadelphia-negative myeloproliferative neoplasms (MPNs): a continuum of different disease entities. Int Rev Cell Mol Biol. 2021;365:1\u201369.","DOI":"10.1016\/bs.ircmb.2021.09.001"},{"key":"968_CR5","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1056\/NEJMcp1816082","volume":"381","author":"A Tefferi","year":"2019","unstructured":"Tefferi A, Pardanani A. Essential thrombocythemia. N. Engl J Med. 2019;381:2135\u201344.","journal-title":"N. Engl J Med"},{"key":"968_CR6","doi-asserted-by":"publisher","first-page":"5857","DOI":"10.1182\/blood-2011-02-339002","volume":"117","author":"A Carobbio","year":"2011","unstructured":"Carobbio A, Thiele J, Passamonti F, Rumi E, Ruggeri M, Rodeghiero F, et al. Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients. Blood. 2011;117:5857\u20139.","journal-title":"Blood"},{"key":"968_CR7","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1111\/j.1365-2141.2004.05277.x","volume":"128","author":"MA Elliott","year":"2005","unstructured":"Elliott MA, Tefferi A. Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. Br J Haematol. 2005;128:275\u201390.","journal-title":"Br J Haematol"},{"key":"968_CR8","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1002\/ajh.26008","volume":"95","author":"A Tefferi","year":"2020","unstructured":"Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management. Am J Hematol. 2020;95:1599\u2013613.","journal-title":"Am J Hematol"},{"key":"968_CR9","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1182\/blood.2022017625","volume":"141","author":"AL Godfrey","year":"2023","unstructured":"Godfrey AL, Green AC, Harrison CN. Essential thrombocythemia: challenges in clinical practice and future prospects. Blood. 2023;141:1943\u201353.","journal-title":"Blood"},{"key":"968_CR10","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s00428-022-03480-8","volume":"482","author":"U Gianelli","year":"2023","unstructured":"Gianelli U, Thiele J, Orazi A, Gangat N, Vannucchi AM, Tefferi A, et al. International Consensus Classification of myeloid and lymphoid neoplasms: myeloproliferative neoplasms. Virchows Arch. 2023;482:53\u201368.","journal-title":"Virchows Arch"},{"key":"968_CR11","first-page":"415","volume":"4","author":"Rose SR, Petersen NJ, Gardner TJ, Hamill RJ, Trautner BW.","year":"2012","unstructured":"Rose SR, Petersen NJ, Gardner TJ, Hamill RJ, Trautner BW. Etiology of thrombocytosis in a general medicine population: analysis of 801 cases with emphasis on infectious causes. J Clin Med Res. 2012;4:415\u201323.","journal-title":"J Clin Med Res"},{"key":"968_CR12","doi-asserted-by":"publisher","first-page":"12367","DOI":"10.2147\/OTT.S287944","volume":"13","author":"GG Loscocco","year":"2020","unstructured":"Loscocco GG, Guglielmelli P, Vannucchi AM. Impact of mutational profile on the management of myeloproliferative neoplasms: a short review of the emerging data. Onco Targets Ther. 2020;13:12367\u201382.","journal-title":"Onco Targets Ther"},{"key":"968_CR13","doi-asserted-by":"publisher","first-page":"5128","DOI":"10.1182\/blood-2012-07-444067","volume":"120","author":"T Barbui","year":"2012","unstructured":"Barbui T, Finazzi G, Carobbio A, Thiele J, Passamonti F, Rumi E, et al. Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). Blood. 2012;120:5128\u201333.","journal-title":"Blood"},{"key":"968_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.94","volume":"5","author":"T Barbui","year":"2015","unstructured":"Barbui T, Vannucchi AM, Buxhofer-Ausch V, De Stefano V, Betti S, Rambaldi A, et al. Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia. Blood Cancer J. 2015;5:e369.","journal-title":"Blood Cancer J"},{"key":"968_CR15","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1002\/ajh.24293","volume":"91","author":"M Haider","year":"2016","unstructured":"Haider M, Gangat N, Lasho T, Abou Hussein AK, Elala YC, Hanson C, et al. Validation of the revised International Prognostic Score of Thrombosis for Essential Thrombocythemia (IPSET-thrombosis) in 585 Mayo Clinic patients. Am J Hematol. 2016;91:390\u20134.","journal-title":"Am J Hematol"},{"key":"968_CR16","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1182\/blood-2012-01-403279","volume":"120","author":"F Passamonti","year":"2012","unstructured":"Passamonti F, Thiele J, Girodon F, Rumi E, Carobbio A, Gisslinger H, et al. A prognostic model to predict survival in 867 World Health Organization\u2013defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment. Blood. 2012;120:1197\u2013201.","journal-title":"Blood"},{"key":"968_CR17","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1111\/bjh.16380","volume":"189","author":"A Tefferi","year":"2020","unstructured":"Tefferi A, Guglielmelli P, Lasho TL, Coltro G, Finke CM, Loscocco GG, et al. Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera. Br J Haematol. 2020;189:291\u2013302.","journal-title":"Br J Haematol"},{"key":"968_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00470-y","volume":"11","author":"P Guglielmelli","year":"2021","unstructured":"Guglielmelli P, Gangat N, Coltro G, Lasho TL, Loscocco GG, Finke CM, et al. Mutations and thrombosis in essential thrombocythemia. Blood Cancer J. 2021;11:77.","journal-title":"Blood Cancer J"},{"key":"968_CR19","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1002\/ajh.26332","volume":"96","author":"GG Loscocco","year":"2021","unstructured":"Loscocco GG, Guglielmelli P, Gangat N, Rossi E, Mannarelli C, Betti S, et al. Clinical and molecular predictors of fibrotic progression in essential thrombocythemia: a multicenter study involving 1607 patients. Am J Hematol. 2021;96:1472\u201380.","journal-title":"Am J Hematol"},{"key":"968_CR20","doi-asserted-by":"crossref","unstructured":"Farrukh F, Guglielmelli P, Loscocco GG, Pardanani A, Hanson CA, De Stefano V, et al. Deciphering the individual contribution of absolute neutrophil and monocyte counts to thrombosis risk in polycythemia vera and essential thrombocythemia. Am J Hematol. 2022;97:E35\u20137.","DOI":"10.1002\/ajh.26423"},{"key":"968_CR21","doi-asserted-by":"crossref","unstructured":"Tefferi A, Loscocco GG, Farrukh F, Szuber N, Mannelli F, Pardanani A, et al. A globally applicable \u201ctriple A\u201d risk model for essential thrombocythemia based on age, absolute neutrophil count, and absolute lymphocyte count. Am J Hematol. 2023;98:1829\u201337.","DOI":"10.1002\/ajh.27079"},{"key":"968_CR22","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1200\/JCO.2017.76.4886","volume":"36","author":"P Guglielmelli","year":"2018","unstructured":"Guglielmelli P, Lasho TL, Rotunno G, Mudireddy M, Mannarelli C, Nicolosi M, et al. MIPSS70: mutation-enhanced international prognostic score system for transplantation-age patients with primary myelofibrosis. J Clin Oncol. 2018;36:310\u20138.","journal-title":"J Clin Oncol"},{"key":"968_CR23","doi-asserted-by":"publisher","unstructured":"McGowan-Jordan J, Hastings RJ, Moore S, editors. An International System for Human Cytogenomic Nomenclature, ISCN 2020. Karger AG; 2020. https:\/\/doi.org\/10.1159\/isbn.978-3-318-06867-2.","DOI":"10.1159\/isbn.978-3-318-06867-2"},{"key":"968_CR24","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","volume":"3","author":"S Schulman","year":"2005","unstructured":"Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3:692\u20134.","journal-title":"J Thromb Haemost"},{"key":"968_CR25","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1002\/ajh.24338","volume":"91","author":"YC Elala","year":"2016","unstructured":"Elala YC, Lasho TL, Gangat N, Finke C, Barraco D, Haider M, et al. Calreticulin variant stratified driver mutational status and prognosis in essential thrombocythemia. Am J Hematol. 2016;91:503\u20136.","journal-title":"Am J Hematol"},{"key":"968_CR26","doi-asserted-by":"publisher","first-page":"E121","DOI":"10.1002\/ajh.23743","volume":"89","author":"A Tefferi","year":"2014","unstructured":"Tefferi A, Wassie EA, Guglielmelli P, Gangat N, Belachew AA, Lasho TL, et al. Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: a collaborative study of 1027 patients. Am J Hematol. 2014;89:E121\u20134.","journal-title":"Am J Hematol"},{"key":"968_CR27","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/ejh.12389","volume":"94","author":"N Gangat","year":"2015","unstructured":"Gangat N, Wassie EA, Lasho TL, Finke C, Ketterling RP, Hanson CA, et al. Mutations and thrombosis in essential thrombocythemia: prognostic interaction with age and thrombosis history. Eur J Haematol. 2015;94:31\u20136.","journal-title":"Eur J Haematol"},{"key":"968_CR28","doi-asserted-by":"publisher","first-page":"e936","DOI":"10.1097\/HS9.0000000000000936","volume":"7","author":"A Alvarez-Larr\u00e1n","year":"2023","unstructured":"Alvarez-Larr\u00e1n A, Cuevas B, Velez P, Noya S, Caballero-Navarro G, Ferrer-Mar\u00edn F, et al. Application of IPSET-thrombosis in 1366 patients prospectively followed from the Spanish registry of essential thrombocythemia. HemaSphere. 2023;7:e936.","journal-title":"HemaSphere"},{"key":"968_CR29","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/leu.2015.277","volume":"30","author":"D Pietra","year":"2016","unstructured":"Pietra D, Rumi E, Ferretti VV, Buduo CAD, Milanesi C, Cavalloni C, et al. Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms. Leukemia. 2016;30:431\u20138.","journal-title":"Leukemia"},{"key":"968_CR30","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1002\/ajh.24377","volume":"91","author":"G Rotunno","year":"2016","unstructured":"Rotunno G, Pacilli A, Artusi V, Rumi E, Maffioli M, Delaini F, et al. Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: a study on 359 patients of the AGIMM group. Am J Hematol. 2016;91:681\u20136.","journal-title":"Am J Hematol"},{"key":"968_CR31","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1182\/blood-2013-11-538983","volume":"123","author":"G Rotunno","year":"2014","unstructured":"Rotunno G, Mannarelli C, Guglielmelli P, Pacilli A, Pancrazzi A, Pieri L, et al. Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. Blood. 2014;123:1552\u20135.","journal-title":"Blood"},{"key":"968_CR32","doi-asserted-by":"publisher","first-page":"e487","DOI":"10.1038\/bcj.2016.98","volume":"6","author":"M Haider","year":"2016","unstructured":"Haider M, Elala YC, Gangat N, Hanson CA, Tefferi A. MPL mutations and palpable splenomegaly are independent risk factors for fibrotic progression in essential thrombocythemia. Blood Cancer J. 2016;6:e487.","journal-title":"Blood Cancer J"},{"key":"968_CR33","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1002\/ajh.24882","volume":"92","author":"A Tefferi","year":"2017","unstructured":"Tefferi A, Betti S, Barraco D, Mudireddy M, Shah S, Hanson CA, et al. Gender and survival in essential thrombocythemia: a two\u2010center study of 1494 patients. Am J Hematol. 2017;92:1193\u20137.","journal-title":"Am J Hematol"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00968-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00968-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00968-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T20:02:07Z","timestamp":1705608127000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00968-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,18]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["968"],"URL":"https:\/\/doi.org\/10.1038\/s41408-023-00968-7","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,18]]},"assertion":[{"value":"17 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10"}}